– Data presentation to include safety, pharmacokinetics (PK), and pharmacodynamics (PD) from all patients, with preliminary efficacy from patients with T-cell lymphomas, in patients with relapsed/refractory non-Hodgkin
– Initiated dosing in a Phase 1/2 trial of ARV-6723, an immuno-oncology oral PROTAC designed to degrade HPK1, a negative regulator of immune activation – – Reaffirmed commitment to share clinical data from three Phase
– $25,000 monetary award to recognize an emerging researcher or research team advancing targeted protein degradation – – Nominations open November 1, 2026, and close December 31, 2026; winner to be recognized in
NEW HAVEN, Conn., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that
– Data showed improvements in an objective measure of impaired eye movement associated with Parkinson’s disease, with a correlation between reductions in LRRK2 cerebrospinal fluid (CSF) biomarkers to these changes in
NEW HAVEN, Conn., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that novel
NEW HAVEN, Conn., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN) ("Arvinas" or the "Company"), a clinical-stage biotechnology company creating a new class of drugs based on targeted
– ARV-6723 is an investigational, oral PROTAC designed to degrade HPK1, a negative regulator of immune activation, in advanced solid tumors – NEW HAVEN, Conn., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc.
NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN) ("Arvinas" or the "Company"), a clinical-stage biotechnology company creating a new class of drugs based on targeted
NEW HAVEN, Conn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN) ("Arvinas" or the "Company"), a clinical-stage biotechnology company creating a new class of drugs based on targeted
– Secured the first-ever regulatory approval of a PROTAC (a type of heterobifunctional protein degrader), VEPPANU, and successfully completed out-licensing to Rigel Pharmaceuticals – – Anticipates sharing clinical
NEW HAVEN, Conn., July 28, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review
NEW HAVEN, Conn., June 04, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced it has recently joined the
NEW HAVEN, Conn., May 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that
NEW HAVEN, Conn., May 18, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company working to create a new class of drugs based on targeted protein degradation, today announced that
